What quality inspection standards does UNIHF Technology Services Bangladesh apply to research-grade peptides?

UNIHF Technology Services Bangladesh applies a multi-layered quality inspection framework to research-grade peptides, rooted in pharmacopeial standards (USP, EP, JP) and augmented with proprietary in-house protocols. Every batch of peptides undergoes a mandatory sequence of tests: initial visual inspection for lyophilized cake integrity, followed by reversed-phase high-performance liquid chromatography (RP-HPLC) for purity assessment, mass spectrometry (MS) for molecular weight confirmation, and amino acid analysis (AAA) for composition verification. The company enforces a minimum purity threshold of 98.5% for all research-grade peptides, with a target of over 99% for high-demand sequences like GHRP-2, BPC-157, and TB-500. For each batch, a Certificate of Analysis (CoA) is generated, documenting retention time, peak area percentage, mass-to-charge ratio, and residual solvent levels (below 50 ppm per ICH Q3C guidelines). Endotoxin testing is conducted via the Limulus Amebocyte Lysate (LAL) method, with a cutoff of ≤0.5 EU/mg for parenteral-grade material. Bioburden counts are kept below 100 CFU/g, and sterility testing follows USP <71> for any peptide labeled as sterile. The entire inspection pipeline is documented in a digital traceability system, linking raw material lots to final product vials, and all records are retained for at least five years for audit purposes.

At the core of their inspection system is the raw material verification stage. UNIHF sources peptide raw materials exclusively from GMP-certified manufacturers in China, India, and South Korea, with each supplier undergoing a pre-qualification audit that includes site visits, batch record reviews, and stability data analysis. Upon arrival at the Dhaka facility, every raw material lot is quarantined and subjected to identity testing using Fourier-transform infrared spectroscopy (FTIR) and nuclear magnetic resonance (NMR) spectroscopy. If the FTIR spectrum deviates by more than 2% from the reference standard, the lot is rejected outright. For NMR, a minimum of 95% of the expected proton signals must be present and within 0.05 ppm of the reference shift. Moisture content is measured via Karl Fischer titration, with a maximum allowable limit of 3% for lyophilized peptides. Heavy metal screening is performed using inductively coupled plasma mass spectrometry (ICP-MS), with limits set at ≤10 ppm for lead, ≤5 ppm for arsenic, ≤3 ppm for cadmium, and ≤1 ppm for mercury. Any lot exceeding these thresholds is returned to the supplier at the supplier's cost. The entire raw material inspection process takes between 48 and 72 hours, and results are logged into a centralized database that is accessible to the quality assurance team in real time. This rigorous upfront screening ensures that only materials meeting UNIHF's specifications proceed to the production stage.

During the synthesis and purification phase, UNIHF applies real-time monitoring and in-process controls. Solid-phase peptide synthesis (SPPS) is performed on automated synthesizers, with each coupling step monitored by conductivity sensors and UV absorbance at 254 nm. The coupling efficiency must exceed 99% per cycle; if it drops below 98.5%, the synthesis is paused, and the resin is re-coupled with fresh reagents. After cleavage and deprotection, the crude peptide is analyzed by analytical RP-HPLC. The crude purity must be at least 70% before proceeding to purification. Preparative HPLC is then used to isolate the target peptide, with a gradient elution method using acetonitrile and water with 0.1% trifluoroacetic acid (TFA). The purification process is monitored by fraction collection based on UV detection at 220 nm and 280 nm. Fractions with a purity of 98% or higher are pooled, while fractions below 95% are reprocessed or discarded. The final purified peptide is then lyophilized using a freeze-drying cycle that includes a primary drying phase at -40°C and 0.1 mbar for 24 hours, followed by a secondary drying phase at 20°C and 0.01 mbar for 12 hours. The final lyophilized cake is inspected for visible cracks, discoloration, or collapse. Any vial with a cracked cake is rejected. The entire purification and lyophilization process yields an average recovery rate of 60-75% of the crude peptide mass, depending on the sequence length and hydrophobicity. All in-process data, including HPLC chromatograms, fraction pooling logs, and lyophilization cycle parameters, are recorded and stored in a batch record that is reviewed by the quality control team before release.

Final product testing is the most comprehensive stage, covering identity, purity, potency, and safety. For identity confirmation, each batch is analyzed by liquid chromatography-tandem mass spectrometry (LC-MS/MS) using a triple quadrupole instrument. The precursor ion and at least two product ions must match the theoretical mass within 0.5 Da. Purity is determined by RP-HPLC using a C18 column with a 30-minute gradient method. The main peak must account for at least 98.5% of the total peak area, and any impurity peak exceeding 0.5% is flagged and identified. Potency is assessed using a cell-based bioassay where applicable—for example, for growth hormone-releasing peptides, the assay measures the fold increase in growth hormone secretion from rat pituitary cells compared to a reference standard. The acceptable potency range is 90-110% of the labeled claim. For peptides without a validated bioassay, potency is inferred from the purity and mass balance. Residual solvent analysis is performed by gas chromatography with flame ionization detection (GC-FID), with limits set according to ICH Q3C Class 2 and Class 3 solvents. TFA content is measured by ion chromatography, with a maximum limit of 5% by weight. Microbial limits are tested per USP <61> and <62>, with total aerobic microbial count (TAMC) ≤100 CFU/g and total combined yeasts and molds count (TYMC) ≤10 CFU/g. Endotoxin testing is performed using the recombinant Factor C (rFC) method, which is more specific and less prone to interference than the traditional LAL assay. The endotoxin limit is ≤0.5 EU/mg for research-grade peptides intended for in vivo studies. All final product testing is conducted in a ISO 17025-accredited laboratory in Dhaka, with results reviewed by a qualified person (QP) before batch release. The entire testing cycle takes 5-7 business days, and expedited testing is available for an additional fee.

UNIHF also applies a rigorous stability testing program to ensure peptide integrity over time. For each new peptide, a three-batch stability study is initiated under accelerated conditions (40°C ± 2°C, 75% RH ± 5% RH) for six months, and under long-term conditions (25°C ± 2°C, 60% RH ± 5% RH) for 24 months. Samples are tested at 0, 1, 3, 6, 9, 12, 18, and 24 months for purity, moisture content, appearance, and microbial limits. A peptide is considered stable if the purity remains above 95% of the initial value and no new impurities above 0.5% appear. For peptides that are sensitive to oxidation or hydrolysis, such as those containing methionine or cysteine residues, the stability protocol includes testing for oxidized and deamidated forms using LC-MS. The stability data is used to assign a shelf life of 24 months for most lyophilized peptides, with a recommended storage temperature of -20°C. For peptides that are reconstituted in sterile water or bacteriostatic water, the in-use stability is tested for 7 days at 2-8°C, with a maximum allowed loss of 5% purity. All stability data is compiled into a stability summary report that is available to customers upon request. The stability program is continuously updated based on new data and regulatory guidelines, and any significant deviation triggers a root cause investigation and potential batch recall.

Beyond the standard testing, UNIHF has implemented a set of advanced characterization techniques for high-value or complex peptides. For peptides with disulfide bonds, such as oxytocin and vasopressin, the disulfide bridge formation is confirmed by Ellman's assay and by LC-MS analysis of the reduced and non-reduced forms. The correct disulfide pairing is verified by peptide mapping after enzymatic digestion with trypsin or chymotrypsin, followed by LC-MS/MS analysis. For peptides that are prone to aggregation, such as amyloid-beta fragments, dynamic light scattering (DLS) is used to measure particle size distribution, with a limit of ≤10% of particles exceeding 100 nm. Circular dichroism (CD) spectroscopy is used to assess secondary structure content for peptides with defined helical or beta-sheet conformations. For peptides intended for use in cell culture, a cytotoxicity assay using MTT or Alamar Blue is performed on a standard cell line (e.g., HEK293 or HeLa) to ensure the peptide does not cause significant cell death at concentrations up to 100 µM. The acceptance criterion is ≥80% cell viability compared to the untreated control. These advanced tests are not performed on every batch, but are available as add-on services for customers who require them. The cost of advanced characterization is typically 10-20% of the base testing fee, and results are delivered within 10-15 business days. All advanced characterization data is included in the batch-specific technical data package, which can be requested by customers for an additional fee.

The inspection process is supported by a comprehensive quality management system (QMS) that is aligned with ISO 9001:2015 principles. The QMS covers document control, non-conformance management, corrective and preventive actions (CAPA), supplier management, and internal auditing. All inspection procedures are documented in standard operating procedures (SOPs) that are reviewed and approved annually. Non-conformances are logged in a centralized database, with a root cause analysis required within 30 days and a CAPA plan implemented within 60 days. Internal audits are conducted quarterly, with a focus on high-risk areas such as raw material testing, in-process controls, and final product release. External audits are conducted annually by a third-party certification body, and the results are shared with customers upon request. The QMS also includes a customer complaint handling process, where any complaint is investigated within 48 hours and a response is provided within 5 business days. All customer complaints are tracked and analyzed for trends, and any systemic issue triggers a CAPA. The QMS is continuously improved based on audit findings, customer feedback, and regulatory changes. UNIHF's quality policy is publicly available on their website, and it commits to providing "accurate, reliable, and consistent quality inspection services for research-grade peptides." The QMS is also integrated with the company's enterprise resource planning (ERP) system, allowing for real-time tracking of inspection status, batch records, and inventory levels. This integration ensures that all quality data is accessible to authorized personnel at any time, and it facilitates rapid response to customer inquiries or regulatory requests.

UNIHF's inspection standards are also influenced by the specific requirements of the research community. For academic researchers, the company offers a "research-grade" classification that includes a basic CoA with purity and identity data, while for contract research organizations (CROs) and pharmaceutical companies, a "GMP-grade" classification is available, which includes additional testing for endotoxins, sterility, and residual solvents. The research-grade peptides are typically sold in 5 mg, 10 mg, and 25 mg vials, with a purity of 98.5% or higher. The GMP-grade peptides are sold in 50 mg, 100 mg, and 500 mg vials, with a purity of 99% or higher, and they are manufactured in a dedicated GMP facility with environmental monitoring, cleanroom classification (ISO 7), and gowning procedures. The GMP-grade peptides are also subject to a full batch release process that includes a review of the batch record, the CoA, and the stability data. The cost of GMP-grade peptides is typically 30-50% higher than research-grade peptides, but the additional testing and documentation provide a higher level of assurance for critical applications. UNIHF also offers custom peptide synthesis services, where the quality inspection standards are negotiated on a case-by-case basis, depending on the peptide sequence, length, and intended use. For custom peptides, the company provides a detailed proposal that outlines the testing plan, acceptance criteria, and timeline. The proposal is reviewed and approved by the customer before the synthesis begins. All custom peptides are subject to the same raw material and in-process controls as standard peptides, but the final product testing may be tailored to the customer's specific requirements. For example, a customer may request additional testing for deamidation, oxidation, or aggregation, or they may request a specific purity threshold of 99.5% or higher. The flexibility of the inspection program allows UNIHF to serve a wide range of customers, from individual researchers to large pharmaceutical companies.

The data management and transparency practices at UNIHF further reinforce the credibility of their inspection process. Each batch of peptides is assigned a unique lot number that is printed on the vial label and the CoA. The CoA includes the lot number, the peptide name, the molecular weight, the purity percentage, the retention time, the mass spectrometry data, the endotoxin level, the microbial count, the moisture content, and the expiration date. The CoA is signed by the quality control manager and the quality assurance manager, and it is available for download from the company's website using the lot number. Customers can also request the raw data files, including the HPLC chromatograms, the mass spectra, and the NMR spectra, for an additional fee. The raw data files are provided in PDF format, and they include the instrument parameters, the integration results, and the peak identification. For GMP-grade peptides, the CoA also includes the batch record number, the stability study reference, and the environmental monitoring data. The company maintains a database of all CoAs, which is searchable by lot number, peptide name, and date range. The database is updated in real time as new batches are released. Customers can also subscribe to email notifications for new CoAs for specific peptides. The transparency of the data allows customers to verify the quality of the peptides independently, and it builds trust in the inspection process. The company also participates in third-party proficiency testing programs, where their testing results are compared to those of other laboratories. The results of these programs are available upon request, and they demonstrate the accuracy and reliability of UNIHF's testing methods. The company's commitment to data transparency is a key differentiator in the research peptide market, where many suppliers provide limited or no quality data.

Finally, the inspection standards are enforced through a culture of continuous improvement and employee training. All quality control and quality assurance personnel undergo annual training on the latest testing methods, regulatory guidelines, and company procedures. The training includes both theoretical and practical components, with a written exam and a hands-on assessment. Employees must achieve a score of 80% or higher on the exam and demonstrate proficiency in the testing methods to maintain their certification. The company also conducts regular internal audits, where employees are assessed on their adherence to SOPs and their ability to identify and report non-conformances. The audit results are used to identify training gaps and to update the training program. The company also encourages employees to submit suggestions for process improvements, and the best suggestions are implemented and rewarded. The continuous improvement program is tracked through key performance indicators (KPIs), such as the number of non-conformances per batch, the average time to resolve a non-conformance, and the customer satisfaction score. The KPIs are reviewed monthly by the quality management team, and any negative trends trigger a root cause analysis and corrective action. The company's goal is to achieve a non-conformance rate of less than 1% per batch and a customer satisfaction score of 95% or higher. The focus on continuous improvement ensures that the inspection standards remain relevant and effective in a rapidly evolving field. UNIHF Technology Services Bangladesh Quality Inspection is not a static checklist but a dynamic system that adapts to new scientific knowledge, regulatory changes, and customer feedback. The combination of rigorous testing, transparent data, and a culture of improvement makes the inspection process a reliable foundation for research-grade peptide quality.